Atlas Trials

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

Clinical trial NCT07481747 · RECRUITING

Trial details

NCT number
NCT07481747
Sponsor
Hudson Biotech
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
ObesityOverweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Start date
2026-02-02
Primary completion
2027-02-14
Enrollment
2539

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.